1-(3-(5-((2-fluoro-4-iodo phenyl)amino)-6,8-dimethyl -2,4,7-trioxo-3,4,6,7-tetra hydropyrido [4,3-d] pyrimidin-1(2H)-yl)phenyl) cyclopropanecarboxamide (Compound 77);

1-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl) amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetra hydropyrido[4,3-d] pyrimidin-1(2H)-yl) phenyl)cyclopropane carboxamide (Compound 78); and

1-(3-(5-((2-fluoro-4-iodophenyl)amino)-3,6,8-trimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro pyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)cyclopropanecarboxamide (Compound 79).

21. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of any one of claims 1-20 and one or more pharmaceutically acceptable carriers, diluents, or excipients.

22. ~~A method for inhibiting MEK enzymes comprising contacting said MEK enzyme with a composition comprising a~~ Use of a compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts as claimed in any one of claims 1-20, in the preparation of medicament for inhibiting MEK enzymes comprising contacting said compound in an amount sufficient to inhibit said enzyme, and wherein said enzyme is inhibited.

23. The ~~method of~~use as claimed in claim 22, wherein said MEK enzyme is MEK kinase.

24. The use as claimed in ~~method of~~ claim 22, wherein said contacting occurs within a cell.

25. Use of a compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or its pharmaceutically acceptable salts, as claimed in any one of claims 1-20, in the preparation of medicament for ~~A method of~~ treatment of a MEK mediated disorder in an individual suffering from said disorder, comprising administering to said individual an effective amount of a composition comprising ~~a~~ said compound. ~~of formula I, Ia, Ib, Ic, their tautomeric forms, their stereoisomers, or their pharmaceutically acceptable salts as claimed in any one of claims 1-20.~~

26. The use as claimed in ~~method of~~ claim 25, further comprising administering an ~~an~~ additional therapy.

27. The use as claimed in ~~method of~~ claim 26, wherein said additional therapy is radiation therapy, chemotherapy, or a combination of both.

28. The use as claimed in ~~method of~~ claim 25, further comprising administering at least one additional therapeutic agent.

29. The ~~method of~~use as claimed in claim 25, wherein said MEK mediated disorder is selected from the group consisting of inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorder, neurological disorders, fibrogenetic disorders, proliferative disorders, hyperproliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases and malignant diseases.

30. The use as claimed in ~~method of~~ claim 25, wherein said MEK mediated disorder is a hyperproliferative disease.

31. The use as claimed in ~~method of~~ claim 25, wherein said MEK mediated disorder is cancer, tumors, leukemias, neoplasms, or carcinomas.

32. The use as claimed in ~~method of~~ claim 25, wherein said MEK mediated disorder is an inflammatory disease.

33. The use as claimed in ~~method of~~ claim 25, wherein said individual is a mammal.

34. Use of a compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or its pharmaceutically acceptable salts, as claimed in any one of claims 1-20, in the preparation of medicament for~~A method for~~ the treatment or prophylaxis of a proliferative disease in an individual in need thereof comprising administering to said individual an effective amount of a composition comprising ~~a~~ said compound. ~~of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or their pharmaceutically acceptable salts as claimed in any one of claims 1-20.~~

35. The use as claimed in~~method of~~ claim 34, wherein said proliferative disease is cancer, psoriasis, restenosis, autoimmune disease, or atherosclerosis.

36. Use of a compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or its pharmaceutically acceptable salts, as claimed in any one of claims 1-20, in the preparation of medicament for ~~A method for~~ the treatment or prophylaxis of an inflammatory disease in an individual in need thereof comprising administering to said individual an effective amount of a composition comprising ~~a~~ said compound. ~~of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or their pharmaceutically acceptable salts as claimed in any one of claims 1-20.~~

37. The use as claimed in~~method of~~ claim 36, wherein said inflammatory disease is rheumatoid arthritis or multiple sclerosis.

38. Use of a compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or its pharmaceutically acceptable salts, as claimed in any one of claims 1-20, in the preparation of medicament ~~A method~~ for degrading, inhibiting the growth of, or killing cancer cells comprising contacting the cells with an effective amount of a composition to degrade, inhibit the growth of, or kill cancer cells, wherein the composition comprises a said compound ~~of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or their pharmaceutically acceptable salts as claimed in any one of claims 1-20~~.

39. Use of a ~~A~~ compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or its pharmaceutically acceptable salts, as claimed in any one of claims 1-20, in the preparation of medicament for ~~method of~~ inhibiting tumor size increase, reducing the size of a tumor, reducing tumor proliferation, or preventing tumor proliferation in an individual in need thereof comprising administering to said individual an effective amount of a composition to inhibit tumor size increase, reduce the size of a tumor, reduce tumor proliferation or prevent tumor proliferation, wherein the composition comprises a said compound. ~~compound of formula I, Ia, Ib, Ic their tautomeric forms, their stereoisomers, or their pharmaceutically acceptable salts, as claimed in any one of claims 1-20.~~